cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mink Therapeutics Inc
17 own
4 watching
Current Price
$1
$0.01
(1.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
49.2M
52-Week High
52-Week High
3.34000
52-Week Low
52-Week Low
0.75000
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization49.2M
icon52-Week High3.34000
icon52-Week Low0.75000
iconAverage Volume0.08M
iconDividend Yield--
iconP/E Ratio--
What does the Mink Therapeutics Inc do?
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More
How much money does Mink Therapeutics Inc make?
News & Events about Mink Therapeutics Inc.
Zolmax
11 months ago
Prime Medicine (NYSE:PRME Get Rating) and MiNK Therapeutics (NASDAQ:INKT Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends...
Ticker Report
11 months ago
Prime Medicine (NYSE:PRME Get Rating) and MiNK Therapeutics (NASDAQ:INKT Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ...
Globe Newswire
1 year ago
Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.In a patient with metastatic gastric cancer who had no response to treatment with pembrolizumab and nivolumab/FOLFOX, agenT-797 induced a partial ...
Ticker Report
1 year ago
MiNK Therapeutics (NASDAQ:INKT Get Rating) had its price target reduced by stock analysts at Evercore ISI from $4.00 to $3.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The firm presently has an outperform rating on the stock. Evercore ...
Globe Newswire
1 year ago
Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-215) and IL-15-...
Frequently Asked Questions
Frequently Asked Questions
What is Mink Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Mink Therapeutics Inc shares?
plus_minus_icon
How can I buy Mink Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Mink Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mink Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Mink Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Mink Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mink Therapeutics Inc?
plus_minus_icon
What percentage is Mink Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mink Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1
$0.01
(1.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00